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Keratoacanthoma (KA) is a benign keratinocytic neoplasm that usually presents as a solitary nodule on sun-
exposed areas, develops within 6–8 weeks and spontaneously regresses after 3–6 months. KAs share features
such as infiltration and cytological atypia with squamous cell carcinomas (SCCs). Furthermore, there are reports
of KAs that have metastasized, invoking the question of whether or not KA is a variant of SCC. To date no
reported criteria are sensitive enough to discriminate reliably between KA and SCC, and consequently there is a
clinical need for discriminating markers. We screened fresh frozen material from 132 KAs and 37 SCCs for gross
chromosomal aberrations by using comparative genomic hybridization (CGH). Forty-nine KAs (37.1%) and 31
SCCs (83.7%) showed genomic aberrations, indicating a higher degree of chromosomal instability in SCCs.
Gains of chromosomal material from 1p, 14q, 16q, 20q, and losses from 4p were seen significantly more
frequently in SCCs compared with KAs (P-values 0.0033, 0.0198, 0.0301, 0.0017, and 0.0070), whereas loss from 9p
was seen significantly more frequently in KAs (P-value 0.0434). The patterns of recurrent aberrations were also
different in the two types of neoplasms, pointing to different genetic mechanisms involved in their
developments.
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INTRODUCTION
Keratoacanthoma (KA) is a common, benign keratinocytic
neoplasm that usually presents as a solitary, dome-shaped,
pink or flesh-colored nodule developing a central keratin-
filled crater. The lesion is usually located to sun-exposed
areas of the skin of elderly persons and is mostly developing
within 6–8 weeks. Since it spontaneously regresses after 3–6
months, KA has by some been considered to be an abortive or
self-healing malignancy (Schwartz, 1994). KA may appear as
multiple lesions, (Grzybowski, 1950; Muir et al., 1967;
Ferguson-Smith et al., 1971), and shows increased incidence
among immunosuppressed patients (Sullivan and Colditz,
1979). The histopathologic diagnosis of KA is based on the
architecture as well as cytologic features, and when a typical
clinical history is known, most KAs can be distinguished from
squamous cell carcinomas (SCCs) (Weedon, 2003; Elder
et al., 2005). However, particularly in the early proliferative
phase, KA shares features with SCC such as infiltration and
cytological atypia. Furthermore, there are reports of KAs that
have metastasized, raising the question of whether KA is a
variant of SCC (Hodak et al., 1993). There are so far no
criteria that are sensitive enough to discriminate reliably
between a KA and SCC, neither histopathology, biomarkers,
biochemical, nor genetic studies (Kerschmann et al., 1994;
Quinn et al., 1994; Cribier et al., 1999; Jensen et al., 1999;
Putti et al., 2004). There is thus a clinical need for markers
that may distinguish between KA and SCC. Previously,
Clausen et al. (2002), found by means of comparative
genomic hybridization (CGH) that about one-third of 70
KAs harbored genomic aberrations, and that some of these
were not shared by cutaneous SCCs, although some aberra-
tions were common for both types of lesions (Clausen et al.,
2002). The numbers of analyzed cutaneous SCCs were,
however, limited.
The aim of the present study was to characterize possible
differences in gross chromosomal aberrations between
KAs and SCCs by screening with CGH in a sufficiently large
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number of lesions. Such differences may point to different
genetic mechanisms responsible for the development of the
two neoplasms.
RESULTS
In the present study, we have analyzed a series of 62 KAs
and 19 SCCs with CGH. To increase the statistical power,
we have also included our previous data on 70 KAs and 10
SCCs (Clausen et al., 2002), and included data on eight
SCCs from another institution (see Materials and Methods). A
total of 132 KAs and 37 SCCs were thus screened for gross
aberrations in the tumor genome using CGH. Genomic
aberrations were found in 49 of 132 KAs (37.1%), and in 31
of 37 SCCs (83.8%), respectively, and the results are reported
in Tables 1 and 2, and for a summary of all aberrations with
comparison of those in KAs and SCCs, see Figure 1.
The average number of aberrations per lesion detected by
CGH was 3.08 and 6.45, respectively, for KAs and SCCs
(Figure 2). In KAs recurrent gains of chromosomal
material from 9q (18.4%), and losses from 3p (18.4%) and
9p (20.4%) were seen at about the same frequency in the
extended material as in the previously reported cases
(Clausen et al., 2002), whereas gains of 1p (12.2.0%)
and 8q (12.2%) were seen less frequently. Gains of
chromosomal material from 3q, 4p, and 19p were also
seen in 12.2% of KAs with genomic aberrations. In SCCs,
recurrent gains from 1p (41.9%), 3q (25.8%), 8q (25.8%), 20q
(25.8%), 19p (19.4%), and 19q (22.6%) were seen, along
with losses from 3p (19.4%) and 4p (16.1%). Although with a
lower frequency, gains from 1q (19.4%), 5p (16.1%), 9q
(12.9%), and 14q (12.9%), as well as losses from 4q (12.9%),
11p (12.9%), 11q (12.9%), 13q (12.9%), and 18q (12.9%)
were also seen. Gains of material from chromosome arms 1p,
14q, 16q, and 20q as well as losses from 4p were seen
significantly more frequently in SCCs compared to KAs
(P-values 0.0033, 0.0198, 0.0301, 0.0017, and 0.0070),
whereas losses from 9p were detected significantly more
frequently in KAs (P-value 0.0434). Figure 3a illustrates that
KAs and SCCs cluster differently based on their respective
numbers of aberrations, whereas Figure 3b illustrates
differences in the cluster patterns of individual lesion from
KAs and SCCs, emphasizing differences in patterns of
recurrent lesions.
DISCUSSION
It is well known that KAs as well as SCCs develop
preferentially on sun-exposed areas of the skin, and that
actinic keratosis as a result of sun damage is a precursor
lesion for SCC (Elder et al., 2005). The reported frequencies of
malignant transformation within actinic keratosis are de-
bated, but recent data indicate a significant frequency of
transformation, possibly higher than 10% (Mittelbronn et al.,
1998). Genetic studies have demonstrated a high frequency
of loss of heterozygosity in actinic keratosis (Rehman et al.,
1994). Contrary to SCCs, no such precursor lesion has been
recognized for KAs, which undergo complete regression in
almost all cases (Weedon, 2003). There are thus distinct
differences in biological characteristics of these two types of
lesions that may be reflecting abrogations of different
signaling pathways.
There are only few reports on KAs that have been
subjected to CGH analysis (Ashton et al., 2005), including
those from our previous study on 70 lesions, of which 36.4%
showed genomic aberrations (Clausen et al., 2002). We
therefore wanted to get a more comprehensive overview of
the genomic alterations aquired by KAs and SCCs, analyzing
and comparing a total of 132 KAs and 37 SCCs. In KAs the
previously reported recurrent gain of genomic material from
9q (18.4%) and losses from 3p (18.4%) and from 9p (20.4%)
were still seen in the extended material with high frequency,
whereas previously reported gains from 1p and 8q in this
study were reduced to 12.2% each. Our data from CGH
analysis of 37 cutaneous SCCs is to our knowledge the largest
data set to date. The recurrent aberrations in SCCs are mainly
different from those in KAs, with gains from 1p (41.9%),
3q(25.8%), 8q(25.8%), 20q(25.8%), 19q(22.6%), and
19p(19.4%), and losses from 3p(19.4%) and 4p(16.1%) being
the most common. Of recurrent aberrations only loss of 3p is
seen to about the same extent in KAs and SCCs, whereas
gains of 3q, 8q, and 19p to a lesser extent also are seen in
KAs.
In addition to sporadic reports about limited numbers of
cutaneous SCCs analyzed by CGH, one research group has
analyzed 15 SCCs and 12 actinic keratosis by CGH (Ashton
et al., 2003). Their conclusion is that numerous genetic
imbalances are shared by actinic keratosis and SCC,
consistent with the former lesion being a precursor for SCC.
The most frequently occurring imbalances of SCCs in our
material, that is, gains of 3q, 8q, and 20q, and loss of 3p, are
in accordance with results reported previously (Ashton et al.,
2003). Gain of material from 1p was the most recurrent
aberration in our study. Scoring of imbalances in this region,
however, may be challenged by the presence of artifacts, and
it is known that many authors do not score imbalances here
(Ashton et al., 2005). This may suggest that imbalances on 1p
in fact are more frequent than reported so far. To overcome
the possibility of false results, we have used reverse
hybridization experiments to confirm our data, that is,
reversed fluorochrome labeling of test and control DNA
(Kallioniemi et al., 1994).
Many of the aberrations in SCCs found by CGH,
that is, þ 3q, þ8q, 3p, are consistent with reports
from cytogenetic studies (Ashton et al., 2005). The
present analyses confirm and extend our previous data
(Clausen et al., 2002), showing that more than one-third
(36.5%) of KAs harbor genetic imbalances, whereas
more than twice as many SCCs (83.8%) showed such
imbalances. We now also show that SCCs harbor on
average about twice as many aberrations per lesion as KAs
with detectable imbalances (6.45 versus 3.08, respectively),
and that in addition to generally increased numbers,
cutaneous SCCs also harbor significantly higher numbers
of specific genetic aberrations than KAs (Figure 3a). The
most significant difference is gain of chromosomal material
from 20q, which was found in eight SCCs and in only one
KA (P-value 0.0017). Gains from 1p, 14q, and 16q, as well
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Table 1. Summary of genetic aberrations in KAs
Tumor Gender TX Gain Loss
K1A-95 M  1q32.3-ter, 4p14-ter, 8q22-ter, 17p 10q, 13qcen-22
K2067A-95 M  1p34.2-ter, 1q, 16p, 19p, 21q 5q21–23.1, 9q21.3–34.2, 13q21.3–32
K2A-95 F + 13q 17p12-ter, 19p, 19q
K3A-95 M + — 3p, 8p12-ter, 9p, 21q21-ter
K2A-96 M + 1p34.1-ter, 9q33-ter, 15q22.3–25, 16p12-ter, 16q23-ter,
17p12-ter, 19p13.2-ter, 19q
—
K2649A-96 F + — 19p13.2-ter, 19q13.2-ter
K7464A-96 M + 5p, 9qcen-22.1, 11qcen-14.1 3pcen-21.3, 5qcen-21, 7q21.1-ter, 9p13-ter, 11p,
11q23.3-ter, 17p13-ter, 19q, 21q22.1-ter
K1 E-96 M + 1q22-ter, 8q24.2-ter, 9q34.1-ter, 20q11.2-ter 1pcen-31.3
K3A-96 F  1p34.2-ter, 5p15.1-ter, 6pcen-22.2, 7p13-ter, 8p22-ter,
8q21.1-ter, 17
2q21.3–32.1, 9p, 13q
K4A-96 F + 7qcen-32, X —
K7A-96 M + 19p —
K2A-97 F  — 3p14.2-ter
K2A-98 F  — 1p34.2-ter, 16p13.2-ter, 19
K3A-98 M + 4p13.2-ter 4q, 15q
K3C-98 M + — 9p, 10pcen-22.2, 10q26.1-ter
K3K-98 M + — 19p
K3G-98 M + — 10q21.1–26.1
K3C-99 F + 8q21.1-ter —
K5A-99 F + X —
K14A-99 M + 17q22-ter —
K16A-99 M + 3q24-ter, 9q 31-ter 3p, 11q22.1-ter
K22B-99 F + 12q24.1-ter —
K1A-00 F + 3p24.1-ter, 3q21-ter, 7q21.1-ter, 9q21.1-ter, 18p, 19q13.2-ter 4q28-ter, 5q14–31.3, 9p, 18q
K3C-00 M + 4p14-ter, 22q12.2-ter —
K4B-00 M + — 3pcen-14.2, 5q12-ter
K1A-01 M + 1p34.3-ter, 1q22–23, 6pcen-23, 6q24-ter, 9p21-cen, 9qcen-31 —
K2A-01 M + 1p36-ter, 16p12–13 —
K3A-01 F + 4p16-ter 3p
K4A-01 M + 19 —
K1A-02 M  — 9p23-ter
K3A-02 F  1p34.3-ter —
K5A-02 F + 4p16-ter —
K6A-02 M + — 9p21-ter
K9A-02 F + 9q34.1-ter 3p, 9p23-ter
K10A-02 M + 18q12.1–21.2, 19q12-ter —
K2A-03 M + 9q21.3–31 —
K5D-03 M + — X
K9A-03 F  — 9p23-ter
K10A-03 M + 8p22-ter, 16p11.2–13.2 —
K21A-03 M + — 15q26.1-ter
K1C-04 M + 9qcen-21.2, 11q13.2-ter 11pcen-15.3
K2A-04 M + 3q, 5p, 8p, 8qcen-24.1, 19pcen-13.2 3p
K2D-04 M + 3q25.1-ter —
K2E-04 M + 8q 9q34.2-ter, 11p
K8A-04 F  3q23-ter 3p13-ter
K10A-04 M + — 4q34-ter
KT27 M  X 17
KT35 (1) M + 19p13.1-ter 9p21-ter
KT46 F + 5q21-23.1, 5q23.3-ter —
Tx+: transplanted patients; Tx: non-transplanted patients.
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as losses from 4p were also observed significantly more
frequently in SCCs than in KAs, whereas losses from 9p were
seen significantly more frequently in KAs (Tables 1 and 2,
Figure 1). Furthermore, the patterns of recurrent aberrations
were also different for the two types of lesions, as illustrated
by the dendrogram in Figure 3b.
Our results clearly show that chromosomal instability
is significantly more frequent in cutaneous SCCs than in
KAs. The presence of different imbalances in the genome of
the two types of lesions may be correlated to their different
biological behavior, and suggests different pathogenetic
pathways for their developments. This is also consistent with
a previous study reporting that loss of heterozygosity was
found more frequently in SCCs than in KAs, with fractional
allelic losses of 32.0 and 1.3%, respectively (Waring et al.,
1996).
Table 2. Summary of genetic aberrations in SCCs
Tumor Gender TX Gain Loss
K2B-95 M + 1p31.3-ter, 1qcen-22, 9q33-ter, 11qcen-14.3,
12q24.1-ter, 15q22.1–25, 16, 17, 19, 20q, 21q21-ter,
22q, X
4q22–31.1, 5q15–23.3, 6qcen-21, 13q14.3–31
K5A-98 M + 1p32.2-ter, 1q32.1-ter, 8q24.1-ter, 19 4q31.2-ter
K9A-99 M + 1qcen-25, 20q —
K3B-00 M + 14q31-ter, 15q24-ter —
K3E-00 M + 1p34.1-ter, 6q16.1-ter, 8q12-ter, 14q24.2-ter, 20 4qcen -31.1
K5C-00 F  8q13–24.2 8p21.1-ter
K7A-02 M  16p12-ter, 19p13.1-ter —
K3B-03 M + 9p23-ter 16p13.1-ter
K14A-03 M + 1p22.1–31.1, 1q, 3q, 5p 2p12-ter, 3p, 4, 5q, 10, 11p15.2-ter,
12p15.1-ter, 13, 16qcen-22, 18
K18A-03 M + 1p31.3-ter —
K18B-03 M + — 3p
K2C-04 M + 5p, 21q11.2–22.2 4p15.3-ter, 18q22-ter
K3A-04 M + 2pcen-21, 2q23–24.1, 6q16.3–24, 7p13-ter,
7q11.2-ter, 13
3, 9q22.3-ter, X
K9C-04 M + — 20q13.3-ter
T18 M + 1p12-ter, 3q13.1-ter, 5p14-ter, 7 11p, 13qcen-22
T20 M + 20p, 20q13–13.3 3p
T24 F  1p34.2-ter, 16q22-ter, 19, 20q12-ter 2, 3p21-ter, 3qcen-31
T28 M  — 16, 18p, 18q22-ter
T34 + 16p, 16qcen-21 9p
T36 (1) M  1p33-ter, 1q21–23, 3q26.3-ter, 8q24.1-ter, 15q, 16p,
19p13.1-ter, 19q13.1–13.2, 20q13.2-ter
—
T38 M + 1p32-ter, 16p13.1–13.3, +16q23-ter, 18, 19p13.1–13.2,
19q13.1–13.2, 20q13.1-ter, 22q12-ter
—
T44 F + 3q25.3–26.1, 4q22–26, 5q14-ter, 14q21.1-ter, 18p 2q35-ter, 9q34.2-ter, 10q26.3-ter, 11p15.3-ter,
14qcen-14.1, 17p, 17qcen-21.3 20p, 21
T47 M + 3q25.3-ter, 6pcen-25.1, 8q21.1-ter, 9q31–34.1 18p, 20q13.1-ter
T59 M  1p36.1-ter, 4p16-ter —
37/00-647 F  1p36, 2p, 5p15-ter, 19q 4p, 7q31-ter, 10, 11p, 11q23-ter
39/00-651 F  8q, 9p, 11p12-ter, 20q 8p12-ter
42/01-61 F  3qcen-26.1 —
43/01-99 F  3q13-ter, 8q21-ter, 9q21-ter, 11p12–13, 12p12.3–13.1 11q23.2–24, Xp11.3-ter
44/01-134 F  1p31-ter, 1q, 19q13.1-ter 4p13–15, 11q14–25, Xp11.2–22.3, Xq12–21
48/01-777 F  5p, 8q 2q36–37.1
49/01-981 F  1p32.1-ter, 3q, 6p, 9q21.3-ter, 14q, 16, 18p11-ter,
22q13, Xq22.1-ter
3p, 7p, 10p, 11q23–25, 13qcen-14.3, 15q15-ter,
17p, 18q21.1-ter
Tx+: transplanted patients; Tx: non-transplanted patients.
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The most significant difference between genetic imbal-
ances in KAs and SCCs in this study was the high degree of
gains of 20q in SCCs. 20q is a region which is frequently
amplified in breast as well as colorectal cancer (Tanner et al.,
1994; Ried et al., 1996). Amplification of the consensus
region 20q13 is seen in about 70% of colorectal cancers
and is associated with increased S-phase fraction as well as
bad prognosis (De Angelis et al., 1999, 2001). Candidate
oncogenes localized to 20q13 are ZNF217, which is
associated with immortality in mammary epithelial cells
(Nonet et al., 2001), and STK6/STK15 which codes for Aurora
A, a kinase important for segregation of chromosomes during
mitosis and which is also linked to tumorigenesis and
development of aneuploidy (Goepfert et al., 2002). Detailed
genetic analysis on these genes will clarify their possible
involvement in SCCs. Recurrent losses from 4p as well as
from 4q are also seen in SCCs in the present study, and allelic
losses from chromosome 4 arms have been shown to
correlate with tumor aggressivness in colorectal cancer
(Arribas et al., 1999). Imbalances of the above-mentioned
chromosomal regions are hardly ever seen in KAs, suggesting
that such aberrations may affect genes inducing infiltrative
and metastatic potential of SCCs. Interestingly, the most
frequently occurring recurrent aberration in SCCs is gain
on chromosome arm 1p, which also, although to a lesser
extent, occurs in KAs. The protooncogene JUN is located at
1p32–31 and encodes for a transcription factor that has been
reported to be overexpressed in human cancers. JUN
regulates cell cycle progression as well as apoptosis,
and it is therefore possible that proliferation of SCC as well
as of KA may be stimulated through 1p amplification and
subsequent JUN overexpression. It is also possible that JUN
amplification in KAs may be related to apoptosis as
demonstrated during regression. In contrast to the recurrent
aberrations discussed above, loss of 9p was seen significantly
more frequently in KAs than in SCCs. It is known that the
tumor suppressor gene CDKN2A (p16INK4A) which is inhibit-
ing cell cycle traverse, is located to 9p21. Many reports
mention 9p deletion as an early aberration that is seen in
histomorphologically normal tissues, including nasopharyn-
geal mucosa, and premalignant tissues (Chan et al., 2002;
Stoehr et al., 2005). Thus, 9p deletion may be associated with
growth advantage in areas with a retained architectural tissue
hierarchy like in KAs, whereas other aberrations may give
selective growth to tissues with disrupted architecture. An
obvious trait of KAs is the maintenance of symmetric
architecture with well-differentiated epithelial strands, which
may have fundamental implication for the surveillance of the
neoplastic cells.
Other overlapping recurrent imbalances of KAs and SCCs
are gains from 3q, 8q, 9q, and 19p, and loss at 3p (Table 2).
Many different genes from these regions may be altered and
stimulate uncontrolled proliferation, one possibility is the
protooncogene C-myc localized to 8q24.
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Figure 1. Karyogram illustrating the distribution of genetic immbalances in 49 KAs (red bars) and 31 SCCs (blue bars). Losses are indicated to the left, and
gains are indicated to the right of chromosomes.
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Figure 2. Genetic imbalances in SSCs and KAs. The two left columns show
fractions of KAs and SCCs with (light gray) and without (dark gray) genetic
imbalances.The two columns to the right show distributions of gains (open
columns) and losses (black columns) among KAs and SCCs with imbalances.
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CGH is a screening method with the advantage that it
allows for simultaneous detection and mapping of amplified,
duplicated, or deleted chromosomal regions of the total
genome of tumors in one hybridization procedure (Kallio-
niemi et al., 1992). Limitations are that balanced aberrations,
such as translocations and inversions, will not be detected,
and that the hybridization target (the normal human
metaphase chromosomes) limits the resolution of the
method. Deleted regions must be as large as 5–10 Mb to be
detected, whereas amplified regions may be detected down
to 1–2 Mb if the degree of amplification is sufficiently large
(Forozan et al., 1997). This implies that the percentages of
lesions with genetic aberrations, as well as the number of
aberrations per lesion reported here, are minimum values.
Methods with higher resolution, such as comparative
hybridization to genomic arrays (array CGH) and positional
hybridization, will be able to reveal more specific genetic
aberrations that may serve to further differentiate between KA
and SCC.
If we assume that KA and SCC are biologically separate
lesions with different pathogenetic background, the presence
of overlapping genetic imbalances detected by CGH must be
considered. First of all, many of the aberrations detected are
probably without influence on tumor progression and cell
death. Secondly, it is well known that sun exposure through
UV irradiation is important for development of KAs as well as
for SCCs. Thus, many of the overlapping aberrations may be
due to DNA damage and selection mechanisms caused by
the common influence of UV. The observation that genetic
aberrations are seen more frequently and are more numerous
in SCC than in KA, may result in abrogation of signaling
pathways in SCC that are intact in KA, the latter possibly
facilitating apoptosis and spontaneous regression of KA.
MATERIALS AND METHODS
Patients
A total number of 132 KAs and 37 SCC were analyzed. One hundred
and twenty-six KAs and 18 SCCs were collected from patients at
the Departments of Dermatology, Surgery, and Plastic Surgery at
Rikshospitalet, University of Oslo, during the years 1995–2004. A
total of 101 KAs and 23 SCCs developed in organ transplant
recipients who received immunosuppressive treatment, whereas the
remaining lesions developed in patients who were not transplanted
or immunosuppressed. Eight of the SCCs lesions were excised and
analyzed in the period of 2000–2001 at the Department of Cancer
Genetics, The Norwegian Radium Hospital, Oslo (Micci et al.,
2003). Center for Cutaneous Research, Barts and the London Queen
Mary’s School of Medicine and Dentistry, University of London, UK,
provided us with DNA extracted from six KAs and 11 SCCs collected
in the period of 2000–2004. The studies have been performed
according to requirements from Institutional Review Board and the
Declaration of Helsinki Principles has been followed.
Histopatholologic evaluation of lesions
Most of the lesions were divided into two halves, one of which was
fixed in formalin, embedded in paraffin, and processed for routine
histopathologic evaluation; the other half was immediately stored at
801C for further processing. From all lesions a cross-section through
the central part encompassing the whole lesion was used for CGH
analysis, tumor tissue thus representing more than 75% of the analyzed
material; microdissection was therefore deemed unnecessary.
Sections were cut at 5mm thickness from the formalin-fixed
material and stained with hematoxylin–eosin for routine histopatho-
logic diagnosis. Criteria used for the diagnosis of KAs and SCCs were
according to Elder et al. (2005). Briefly, KAs were characterized
by symmetrical appearance with a centrally located, keratin-filled
crater with overhanging epithelial lips or shoulders. Epithelial
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Figure 3. Dendrograms of SCCs and KAs. (a) Cluster dendrogram illustrating that SCCs (black letters) cluster mainly to the left and reveal generally a higher
numbers of aberrations per lesion compared to KAs (red letters). (b) Group dendrogram illustrating differences between SCCs (upper row) and KAs (lower row) in
frequency of individual aberration, consistent with differences in recurrent aberrations. High frequency, dark shade, and low frequency, light gray.
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strands, often with ground glass appearance, were penetrating
dermis from the center of the lesions. According to generally
accepted criteria, and based on previous findings where no
significant genomic differences by CGH analysis could be demon-
strated in bulk tumor DNA between KAs with and without infiltrating
growth and atypia (Clausen et al., 2002), we have included all such
lesions, irrespective of the degree of cellular atypia and infiltration.
Only SCCs that were not crateriform with possible confusion with
KAs were included. The diagnoses were given by one of the authors
(O.P.F.C.), who is an experienced dermatopathologist.
CGH
CGH was performed on fresh frozen tissue according to a previously
described protocol (De Angelis et al., 1999, 2001). Normal reference
DNA was Texas-Red or Spectrum Red labeled, whereas tumor DNA
was labeled with either FITC or Spectrum Green, respectively. A
positive control using the cell line MPE 600 and a negative control
were usually processed in order to control for artifacts. All samples
that had possible artifacts were either subjected to rehybridization
with reversed fluorochrome labeling of test and control DNA (dye
swap) to confirm true aberrations, or – in a few cases where no more
DNA was available – areas with possible artifacts were excluded
from the data set. Amplifications and deletions were scored if the
red/green ratio was above 1.15 or below 0.85, respectively.
Statistics
The open-source environment and programming language R,
(R Development CoreTeam, 2004), was used for statistical analysis
of chromosomal aberrations. Differences between lesions were
analyzed as contingency tables for each aberration using the Fisher’s
exact test with two-sided P-values calculated as defined by Agresti
(1992), where Po0.05 was considered significant. Also a binary
matrix was made to explore possible correlations between patterns
of chromosome arm aberrations of individual tumors. Gains or losses
of whole chromosomes were scored as two events related to each
chromosome arm. Two separate aberrations (both gains or both
losses) on the same arm were scored as one change, whereas one
gain and loss on the same arm were recorded as two separate events.
This binary matrix was used to build a frequency matrix of
aberrations, where the sum of one aberration in a tumor type was
divided by the total number of samples of the particular tumor type
analyzed in this study. This weighted matrix was used as input for
hierarchical clustering in R (complete hierarchical clustering with
euclidian distance metric).
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